Pilot Study Tests CAR T-Cell Immunotherapy in Glioblastomas
Science Translational Medicine reports results of phase 1 safety study of autologous CAR T cells targeted to EGFR variant III in glioblastoma patients.
Read moreFDA Approval Recommendation for CAR T-Cell Therapy
FDA advisory committee unanimously approves first personalized cellular therapy developed at Penn for pediatric and young adult leukemia.
Read moreTumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
A new Penn Medicine preclinical study in Cell, "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade," suggests that an existing drug known as a JAK in
Read moreReengineering Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease
In a Science study with potentially major implications for the future treatment of autoimmunity and related conditions, co-senior author
Read moreScience Paper Describes Reengineered Chimeric Antigen Receptor T Cells for Targeted Therapy of Autoimmune Disease
Application could open up anti-cancer CAR approach to treatment for a much wider range of diseases, including autoimmunity and transplant rejection.
Read moreDouble Targeted CAR-T Scores in Preclinical Cancer Study for Solid Tumors
Paper in Immunity describes CAR T-Cells' effectiveness in mouse models of pancreatic cancer.
Read more
